Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Change in Accured Expenses (2018 - 2025)

Inmune Bio's Change in Accured Expenses history spans 8 years, with the latest figure at -$170000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 113.0% year-over-year to -$170000.0; the TTM value through Sep 2025 reached -$3.1 million, down 144.67%, while the annual FY2024 figure was -$1.4 million, 150.54% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$170000.0 at Inmune Bio, down from $473000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.2 million in Q4 2023 and bottomed at -$4.1 million in Q4 2024.
  • The 5-year median for Change in Accured Expenses is $88000.0 (2021), against an average of $208789.5.
  • The largest annual shift saw Change in Accured Expenses plummeted 7013.33% in 2022 before it skyrocketed 4041.67% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $88000.0 in 2021, then skyrocketed by 1878.41% to $1.7 million in 2022, then surged by 142.73% to $4.2 million in 2023, then crashed by 195.86% to -$4.1 million in 2024, then skyrocketed by 95.8% to -$170000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Change in Accured Expenses are -$170000.0 (Q3 2025), $473000.0 (Q2 2025), and $659000.0 (Q1 2025).